A carregar...
A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease
PURPOSE: Preclinical evidence indicates that the bone marrow microenvironment provides a protective niche for leukemic stem cells, allowing them to evade the effects of BCR-ABL tyrosine kinase inhibitors (TKIs), but that targeting of the JAK-STAT pathway with the JAK2 inhibitor ruxolitinib increases...
Na minha lista:
| Publicado no: | Leuk Res |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7787269/ https://ncbi.nlm.nih.gov/pubmed/30340199 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2018.10.002 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|